Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
AACR Annual Meeting 2026 · San Diego, CA
19 shown of 9,164 total abstracts
  1. Abstract 65662026-04-02 · 18:00 CT · S100A
    Long-term follow-up of Keytruda 1L for RCC: KEYNOTE-557
    C. Saura, S. Tolaney, A. Spira, et al. · National Cancer Center Japan
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  2. Abstract 62512026-04-05 · 15:15 CT · E450
    Quality of life outcomes with Opdivo in patients with RCC
    M. Reck, M.C. Garassino, C. Robert, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  3. Abstract 66662026-04-01 · 18:00 CT · Hall B1
    Quality of life outcomes with Keytruda in patients with RCC
    M.C. Garassino, C. Robert, E. Winer, et al. · Institut Gustave Roussy
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  4. Abstract 65542026-04-02 · 19:45 CT · Arie Crown Theater
    CheckMate-631: Opdivo (nivolumab) 2L in RCC
    S. Peters, J. Brahmer, G. Curigliano, et al. · Royal Marsden Hospital
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  5. Abstract 62512026-04-02 · 21:00 CT · S406
    CheckMate-439: Opdivo (nivolumab) 2L in RCC
    M. Reck, H. Borghaei · University of Chicago
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  6. Abstract 69122026-04-04 · 21:45 CT · Hall B1
    Long-term follow-up of Keytruda adjuvant for RCC: KEYNOTE-357
    M.C. Garassino, H. Rugo · Massachusetts General Hospital
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  7. Abstract 67592026-04-01 · 19:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-429 study)
    H. Borghaei, S. Tolaney, J. Brahmer, et al. · Chinese University of Hong Kong
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  8. Abstract 61062026-04-03 · 21:45 CT · S100A
    CheckMate-75: Opdivo (nivolumab) maintenance in RCC
    S. Tolaney, G. Curigliano · Institut Gustave Roussy
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  9. Abstract 63402026-04-04 · 15:45 CT · S100A
    Long-term follow-up of Opdivo 3L+ for RCC: CheckMate-102
    M. Krop, P. Schmid, R. Herbst, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  10. Abstract 60602026-04-02 · 19:45 CT · Hall B1
    Real-world effectiveness of Opdivo vs standard of care in RCC
    J. Brahmer, M. Krop, G. Curigliano · Royal Marsden Hospital
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  11. Abstract 62382026-04-04 · 21:15 CT · S100A
    Long-term follow-up of Keytruda maintenance for RCC: KEYNOTE-279
    A. Spira, N. Rizvi · MD Anderson Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  12. Abstract 66302026-04-03 · 18:15 CT · E450
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-461 study)
    M. Krop, S. Tolaney, S. Modi, et al. · Cleveland Clinic
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  13. Abstract 62402026-04-01 · 20:45 CT · S406
    Real-world effectiveness of Keytruda vs standard of care in RCC
    M. Krop, L. Paz-Ares, G. Curigliano, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  14. Abstract 67542026-04-04 · 14:45 CT · E450
    KEYNOTE-710: Keytruda (pembrolizumab) 1L in RCC
    S. Modi, H. Rugo, T. Mok, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  15. Abstract 65062026-04-03 · 18:00 CT · E450
    Long-term follow-up of Opdivo neoadjuvant for RCC: CheckMate-223
    S. Peters, T. Mok · University of Chicago
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  16. Abstract 65702026-04-05 · 14:30 CT · Hall B1
    KEYNOTE-432: Keytruda (pembrolizumab) maintenance in RCC
    J. Brahmer, S. Modi · Stanford Cancer Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  17. Abstract 60842026-04-03 · 14:30 CT · Arie Crown Theater
    KEYNOTE-699: Keytruda (pembrolizumab) adjuvant in RCC
    N. Rizvi, L. Paz-Ares, J. Brahmer · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  18. Abstract 67732026-04-04 · 19:00 CT · S406
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-494 study)
    E. Winer, R. Herbst · National Cancer Center Japan
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  19. Abstract 66622026-04-03 · 14:45 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-985
    P. Schmid, J. Brahmer, S. Antonia, et al. · Royal Marsden Hospital
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.